Investing.com - Financial Markets Worldwide
📈 69% of S&P 500 stocks beating the index - a historic record! Pick the best ones with AI.See top stocks

BRIEF-Valeant Pharmaceuticals in 2016, expect to generate about 30% of revenue outside the U.S.

Published 2015-09-28, 08:18 a/m
© Reuters. BRIEF-Valeant Pharmaceuticals in 2016, expect to generate about 30% of revenue outside the U.S.
BHC
-

Sept 28 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO :
* In 2016, expect to generate approximately 30% of revenue outside the U.S
* In 2016, expect high single-digit/low double-digit growth in emerging markets
and 3-5% growth in ex-U.S. developed markets
* Expect approximately 20% of 2016 revenue to come from U.S. businesses
* Dermatology, ophthalmology rx and dentistry rx 2016 revenue is expected to
represent approximately 20% of revenue
* Expect the Salix business to represent approximately 20% of 2016 revenue
* Expect remaining approximately 10% of business in 2016 to come from neuro and
other portfolio

* Source text (http://1.usa.gov/1OBQo9r)

* Further company coverage VRX.TO

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.